Home › NDC Lookup › Ingredients › Sulfacetamide Sodium › 24208-0670-04
Sulfacetamide Sodium 100 mg/mL Solution/ Drops — NDC 24208-0670-04 package photo
Label image from the product's FDA listing (DailyMed) — may show a different pack size or an older label revision.

Sulfacetamide Sodium 100 mg/mL Solution/ Drops — NDC 24208-670-04 (Billing 24208-0670-04)

by Bausch & Lomb Incorporated · 1 BOTTLE, DROPPER in 1 CARTON / 15 mL in 1 BOTTLE, DROPPER

This is a package of Sulfacetamide Sodium 100 mg/mL Solution/ Drops from Bausch & Lomb Incorporated, marketed since Dec 1994 and currently FDA-listed; retail pharmacies pay about $1.96 per mL (NADAC). It is this product's only package size.

NDC 24208-0670-04
🏷️ FDA NDC (as labeled) 24208-670-04 billing pads the product segment with a zero
Rx only Generic On market Non-controlled ⇄ Compare with another NDC
🗂️ FDA directory synced Oct 1, 2026 · this listing last changed Jul 24, 2026 · sources: openFDA · FDA label (DailyMed) · FDA Orange & Purple Book · First Databank · CMS NADAC, ASP, Medicare & Medicaid · RxNorm
📋 All sources & update times →

This page is curated, coded, and maintained by

Compiled from public FDA, CMS, DailyMed, NADAC, and related drug data sources. Editorial policy

Identity & classification

Regulatory identifiers FDA, NLM and CMS codes for this package

FDA NDC (as labeled) 24208-670-04
Product NDC 24208-670
11-digit billing NDC 24208067004
NCPDP billing unit ML — per mL (volume)
RxCUI 1006120
UNII 4NRT660KJQ
Application # ANDA040066
SPL Set ID 6c1b2658-e756-4f31-9bc8-f99a0baa4637
Established class (EPC) Sulfonamide Antibacterial
Chemical class Sulfonamides
DEA schedule Non-controlled
Marketing category ANDA
Marketing status On market
FDA listing status Listed (active directory)
Marketing start 1994-12-28
Route OPHTHALMIC
Dosage form SOLUTION/ DROPS
Substance SULFACETAMIDE SODIUM
TE code (Orange Book) AT · RLD · RS

Drug-database identifiers Medi-Span GPI and First Databank GCN / HICL / AHFS classification

GPI-14 86102010102010
GPI class Sulfacetamide Sodium
GCN Seq No 007920
GCN 33340
HICL code 003345
Ingredient (HICL) Sulfacetamide Sodium
HIC1 code Q
Therapeutic class — broad (HIC1) Ear/Eye/Nose/Rectum/Topical/Vagina/Other
HIC2 code Q6
Therapeutic class — intermediate (HIC2) Ophthalmic Preparations
HIC3 code Q6S
Therapeutic class — specific (HIC3) Eye Sulfonamides
AHFS code 52:04.04.00
AHFS class Antibacterials (52:04)
FDB label name SULFACETAMIDE 10% EYE DROPS
FDB brand name Sulfacetamide Sodium
Legend status F — Federal legend — prescription drug or device
Quick answers
  • GSN (GCN sequence number): 007920
  • GCN: 33340
  • GPI-14 (Medi-Span): 86102010102010
  • HICL (First Databank): 003345
  • AHFS class code: 52:04.04.00
  • RxCUI (RxNorm): 1006120
Why two NDCs? The FDA registers this code as 24208-670-04 — a 5-3-2 layout, and that's what's printed on the package and shown on DailyMed. For insurance claims, every NDC is standardized to a uniform 11-digit 5-4-2 format by adding a zero to the product segment → 24208-0670-04. Same drug, same package — only the format differs.
Where does this data come from?
Identifiers from the FDA openFDA NDC Directory and Structured Product Labeling; RxCUI from RxNorm (NLM); GPI from Medi-Span; GCN / HIC / AHFS / legend from First Databank.

RxNorm drug class

This medicine belongs to the Sulfonamide Antibacterial class.

Pharmacologic class Sulfonamide Antibacterial
Drug family (ATC) Antiinfectives for treatment of acne, Sulfonamides
Where does this data come from?
Therapeutic classes from RxNorm RxClass (U.S. National Library of Medicine) — Established Pharmacologic Class (FDA), ATC drug family (WHO) and mechanism of action, matched by this product’s RxCUI.

Clinical

Label name SULFACETAMIDE 10% EYE DROPS Ingredient Sulfacetamide Sodium
📖 What it is MedlinePlus · NLM

Ophthalmic sulfacetamide stops the growth of bacteria that cause certain eye infections. It is used to treat eye infections and to prevent them after injuries.

Read the full MedlinePlus article ↗
📗 Our plain-language guide HelloPharmacist
  • It treats conjunctivitis (pink eye) and other superficial eye infections caused by susceptible bacteria. It is also used with sulfonamide medicine given through the body for tracho...
  • You place one or two drops into the lower pocket of the affected eye. For pink eye, that's usually every two to three hours at first. Your doctor may space the doses out as you imp...
  • The most common are irritation, stinging and burning in the eye. Some people notice eye redness or a secondary infection. These are usually the things to mention to your pharmacist...
  • Stop the drops and call right away if you get a skin rash or any sign of an allergic reaction. Rarely, sulfa drugs cause serious, even fatal, reactions affecting the skin, liver or...
📖 Read our full Sulfacetamide Ophthalmic guide →

Supplement & herbal interactions

🌿 Drug–supplement interaction checker →
Where does this data come from?
Plain-language summary from MedlinePlus (U.S. National Library of Medicine); supplement & herbal interactions and nutrient depletion data from the Natural Medicines database; our full guide is HelloPharmacist editorial content.

Pricing

A drug doesn't have one price. Each row is a different public payment system, and none is what you'd pay at the counter — that depends on your insurance. The ⓘ on each row explains what it measures.

Price systemPer mLPer package
Retail pharmacies payNADAC · weekly $1.962 $29.43 / 15 ml
Medicaid paysCMS SDUD · 12 mo $2.51 $37.59 / 15 ml
Medicare drug plans payPart D · Q2 2026 $1.86 $27.95 / 15 ml
NADAC price history (per mL) — tap or hover for the price & month
Jan 2022 Aug 2022 Jan 2026 Sep 2026 $2.604 $1.851
▼ Down 15% over the last 24 months.
Where does this data come from?
NADAC (National Average Drug Acquisition Cost) is the CMS weekly pharmacy-acquisition-cost survey — what pharmacies pay. ASP (Average Sales Price) is the CMS Medicare Part B drug-payment file, published quarterly. Medicaid pays is computed by us from CMS State Drug Utilization Data (total reimbursed ÷ units, trailing 12 months) — gross of rebates and inclusive of dispensing fees, so it reflects what Medicaid paid, not an acquisition cost. Medicare drug plans pay is the median negotiated point-of-sale unit cost across plans listing this NDC in the CMS quarterly Prescription Drug Plan pricing files, before rebates. The VA pays is the federal contract price (FSS, and the statutory Big 4 ceiling where listed) from the VA National Acquisition Center pharmaceutical price file. All are free public government data; each measures a different payer, so the figures are not directly comparable.

Packaging — all sizes for this product

Package NDCDescription Marketing startMarketing endStatus
24208-0670-04 You're viewing this Main listing 1 BOTTLE, DROPPER in 1 CARTON / 15 mL in 1 BOTTLE, DROPPER 1994-12-28 — Active

Therapeutic equivalents

ProductLabelerPackNADAC/unitTEStatusPrice vs. this
Sulfacetamide Sodium 100 mg/mLthis 24208-0670-04 Bausch 1 bottle $1.962 AT Availability likely —
Sulfacetamide Sodium 100 mg/mL 50090-0246-00 A-S 1 bottle — AT FDA listed —
Sulfacetamide Sodium 100 mg/mL 68071-5123-05 NuCare 15 ml — AT FDA listed —
Sulfacetamide Sodium 100 mg/mL 68788-9871-01 Preferred 15 ml — AT FDA listed —
Sulfacetamide Sodium 100 mg/mL 71205-0689-15 Proficient 1 bottle — AT FDA listed —
Sulfacetamide Sodium 100 mg/mL 76420-0076-15 Asclemed 15 ml — AT FDA listed —
Sulfacetamide Sodium 100 mg/mL 76420-0090-15 Asclemed 15 ml — AT FDA listed —
About this product: this is a generic version of the medicine. FDA equivalence ratings are shown when available, and other versions are listed above, least expensive first.
Where does this data come from?
Equivalents are other NDCs of the same ingredient, form and route from the openFDA NDC Directory, ranked least-expensive-first by NADAC. Therapeutic-equivalence (AB) ratings come from the FDA Orange Book; biologics use the FDA Purple Book for biosimilar & interchangeable status.

Availability & generic status

🏛️
1994
On the market since
Dec 1994
📍
2026
Currently FDA-listed
32 years listed
🔓
·
Generic on the market
this product is a generic
✅This is a generic drug

This product is an FDA-approved generic. Other versions of the same drug are listed under Therapeutic equivalents, least expensive first.

Where does this data come from?
Patents and exclusivity from the FDA Orange Book (small-molecule drugs), refreshed from public FDA data. Generic launch timing is an estimate, not a guarantee.

Inactive Ingredients / Excipients

Inactive ingredients, also called excipients, are components of the drug product other than the active ingredient. They may include fillers, dyes, coatings, preservatives, flavors, or other formulation ingredients.

💡 Tap an ingredient (hover on desktop) to see what it is and why it’s used.

  • UNII 4GFU244C4J
    Methylcellulose is a plant-based thickening agent made from cellulose. It acts as a binder to hold pill ingredients together and as a bulking agent to add texture and consistency to liquid or semi-solid medicines.
  • UNII A2I8C7HI9T
    Methylparaben is a preservative derived from benzoic acid that prevents growth of bacteria, fungi, and mold in medicines. It extends the product's shelf life and maintains safety during storage.
  • UNII Z8IX2SC1OH
    Propylparaben is a chemical preservative used to prevent bacterial and fungal growth in medicines and personal care products. It helps extend shelf life and maintain product safety during storage.
  • UNII KH7I04HPUU
    A salt compound made from sodium and phosphoric acid, used as a buffer to help maintain a stable pH level in the medicine, and sometimes as a binder or filler in tablets and capsules.
  • UNII HX1032V43M
    Sodium thiosulfate is a salt compound used in medicines as a buffer and pH regulator. It helps stabilize the medication and may also serve as a preservative or antioxidant to maintain product quality.
  • UNII 059QF0KO0R
    Water is a liquid solvent that dissolves and mixes ingredients together in liquid medicines, syrups, and injections. It helps distribute the active drug evenly throughout the product.

6 inactive ingredients listed in the exact product block matched to this NDC.

Where does this data come from?
Data sourced from official FDA Structured Product Labeling (SPL) via DailyMed — ingredient classCode="IACT" elements from the exact product block matched by this NDC. Label-section narrative from DailyMed / the openFDA label index is shown separately when available.

Inactive ingredient FAQ

Are inactive ingredients the same for every manufacturer?
No. Inactive ingredients can differ by manufacturer, dosage form, strength, and package / product version.
Why might an inactive ingredient be missing?
Some SPLs do not provide a complete structured inactive-ingredient list, and older or unusual labels may only include the information in narrative text.
Can inactive ingredients matter?
Yes. They can matter for allergies, intolerances, dyes, gluten / lactose concerns, preservatives, and formulation differences — but confirm with a pharmacist or the manufacturer when it’s clinically important.

Manufacturer & labeler

LabelerBausch & Lomb Incorporated
Application holderBAUSCH AND LOMB INC
FDA applicationANDA040066 (ANDA)
Labeler code24208
First marketedDec 1994
Product typeHuman Prescription Drug
Portfolio92 products on file
The labeler markets the product; the application holder owns the FDA approval. They’re often the same company but can differ (e.g. a repackager or an authorized generic). A mailing address / phone appears here when the manufacturer includes it in the product’s FDA label (not all do).
Where does this data come from?
Labeler, application holder and registered establishment from the FDA openFDA NDC Directory and Drugs@FDA; address/contact from the product’s FDA label.

Full prescribing information FDA SPL

The complete FDA label for this product — the official prescribing information, verbatim, section by section. Jump with a chip, search within the label, or expand everything.
🎯 Indications and Usage ⏱️ Dosage and Administration ⛔ Contraindications ⚠️ Warnings 🤒 Adverse Reactions 🔄 Drug Interactions 🤰 Pregnancy 🧒 Pediatric Use 🧬 Clinical Pharmacology 📦 How Supplied / Storage and Handling 📋 Description 💬 Information for Patients ⚠️ Precautions 🍼 Nursing Mothers 📄 Carcinogenesis, Mutagenesis, Impairment of Fertility 📄 Package Label / Principal Display Panel
🎯 Indications and Usage 80 words ▾

INDICATIONS AND USAGE Sulfacetamide sodium ophthalmic solution USP, 10% is indicated for the treatment of conjunctivitis and other superficial ocular infections due to susceptible microorganisms, and as an adjunctive in systemic sulfonamide therapy of trachoma: Escherichia coli, Staphylococcus aureus, Streptococcus pneumoniae, Streptococcus (viridans group), Haemophilus influenzae, Klebsiella species, and Enterobacter species. Topically applied sulfonamides do not provide adequate coverage against Neisseria species, Serratia marcescens and Pseudomonas aeruginosa .

A significant percentage of staphylococcal isolates are completely resistant to sulfa drugs.

⏱️ Dosage and Administration 78 words ▾

DOSAGE AND ADMINISTRATION For conjunctivitis and other superficial ocular infections: Instill one or two drops into the conjunctival sac(s) of the affected eye(s) every two to three hours initially. Dosages may be tapered by increasing the time interval between doses as the condition responds. The usual duration of treatment is seven to ten days.

For trachoma: Instill two drops into the conjunctival sac(s) of the affected eye(s) every two hours. Topical administration must be accompanied by systemic administration.

⛔ Contraindications 24 words ▾

CONTRAINDICATIONS Sulfacetamide sodium ophthalmic solution USP, 10% is contraindicated in individuals who have a hypersensitivity to sulfonamides or to any ingredient of the preparation.

⚠️ Warnings 82 words ▾

WARNINGS FOR TOPICAL EYE USE ONLY - NOT FOR INJECTION. FATALITIES HAVE OCCURRED, ALTHOUGH RARELY, DUE TO SEVERE REACTIONS TO SULFONAMIDES INCLUDING STEVENS-JOHNSON SYNDROME, TOXIC EPIDERMAL NECROLYSIS, FULMINANT HEPATIC NECROSIS, AGRANULOCYTOSIS, APLASTIC ANEMIA AND OTHER BLOOD DYSCRASIAS. Sensitizations may recur when a sulfonamide is readministered, irrespective of the route of administration.

Sensitivity reactions have been reported in individuals with no prior history of sulfonamide hypersensitivity. At the first sign of hypersensitivity, skin rash or other serious reaction, discontinue use of this preparation.

🤒 Adverse Reactions 89 words ▾

ADVERSE REACTIONS Bacterial and fungal corneal ulcers have developed during treatment with sulfonamide ophthalmic preparations. The most frequently reported reactions are local irritation, stinging and burning. Less commonly reported reactions include non-specific conjunctivitis, conjunctival hyperemia, secondary infections and allergic reactions.

Fatalities have occurred, although rarely, due to severe reactions to sulfonamides including Stevens-Johnson syndrome, toxic epidermal necrolysis, fulminant hepatic necrosis, agranulocytosis, aplastic anemia, and other blood dyscrasias (see WARNINGS ). To report SUSPECTED ADVERSE REACTIONS, contact Bausch & Lomb Incorporated at 1-800-553-5340 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch .

🔄 Drug Interactions 9 words ▾

Drug Interactions Sulfacetamide preparations are incompatible with silver preparations.

🤰 Pregnancy 85 words ▾

Pregnancy Animal reproduction studies have not been conducted with sulfonamide ophthalmic preparations. Kernicterus may occur in the newborn as a result of treatment of a pregnant woman at term with orally administered sulfonamides. There are no adequate and well-controlled studies of sulfonamide ophthalmic preparations in pregnant women, and it is not known whether topically applied sulfonamides can cause fetal harm when administered to a pregnant woman.

This product should be used in pregnancy only if the potential benefit justifies the potential risk to the fetus.

🧒 Pediatric Use 17 words ▾

Pediatric Use Safety and effectiveness in infants below the age of two months have not been established.

🧬 Clinical Pharmacology 121 words ▾

CLINICAL PHARMACOLOGY Microbiology: The sulfonamides are bacteriostatic agents and the spectrum of activity is similar for all. Sulfonamides inhibit bacterial synthesis of dihydrofolic acid by preventing the condensation of the pteridine with aminobenzoic acid through competitive inhibition of the enzyme dihydropteroate synthetase. Resistant strains have altered dihydropteroate synthetase with reduced affinity for sulfonamides or produce increased quantities of aminobenzoic acid.

Topically applied sulfonamides are considered active against susceptible strains of the following common bacterial eye pathogens: Escherichia coli, Staphylococcus aureus, Streptococcus pneumoniae, Streptococcus (viridans group), Haemophilus influenzae, Klebsiella species, and Enterobacter species. Topically applied sulfonamides do not provide adequate coverage against Neisseria species, Serratia marcescens and Pseudomonas aeruginosa . A significant percentage of staphylococcal isolates are completely resistant to sulfa drugs.

📦 How Supplied / Storage and Handling 95 words ▾

HOW SUPPLIED Sulfacetamide sodium ophthalmic solution USP, 10% is supplied in a plastic squeeze bottle with a controlled drop tip in the following size: NDC 24208-670-04 15 mL bottle Storage: Store between 2°C to 25°C (36°F to 77°F). Sulfonamide solutions, on long standing, will darken in color and should be discarded. Keep out of reach of children.

Distributed by: Bausch & Lomb Americas Inc. Bridgewater, NJ 08807 USA Manufactured by: Bausch & Lomb Incorporated Tampa, FL 33637 USA © 2023 Bausch & Lomb Incorporated or its affiliates Revised: August 2023 9113204 (Folded) 9113304 (Flat) donotuse

📋 Description 71 words ▾

DESCRIPTION Sulfacetamide sodium ophthalmic solution USP, 10% is a sterile, topical antibacterial agent for ophthalmic use. The active ingredient is represented by the following structural formula: Chemical name: N -Sulfanilylacetamide monosodium salt monohydrate. Each mL contains: Active: sulfacetamide sodium, 100 mg/mL (10%); Inactives: methylcellulose, purified water, sodium thiosulfate.

Sodium phosphate monobasic may be added to adjust pH (6.8-8.0). Preservatives: methylparaben 0.05% and propylparaben 0.01%. The osmolality range is 700-1300 mOsm/kg. chem

💬 Information for Patients 19 words ▾

Information for Patients To avoid contamination, do not touch tip of container to the eye, eyelid or any surface.

⚠️ Precautions ~1 min read ▾

PRECAUTIONS General Prolonged use of topical antibacterial agents may give rise to overgrowth of nonsusceptible organisms including fungi. Bacterial resistance to sulfonamides may also develop. The effectiveness of sulfonamides may be reduced by the para-aminobenzoic acid present in purulent exudates.

Sensitization may recur when a sulfonamide is readministered irrespective of the route of administration and cross-sensitivity between different sulfonamides may occur. At the first sign of hypersensitivity, increase in purulent discharge, or aggravation of inflammation or pain, the patient should discontinue use of the medication and consult a physician (see WARNINGS ). Information for Patients To avoid contamination, do not touch tip of container to the eye, eyelid or any surface.

Drug Interactions Sulfacetamide preparations are incompatible with silver preparations. Carcinogenesis, Mutagenesis, Impairment of Fertility No studies have been conducted in animals or in humans to evaluate the possibility of these effects with ocularly administered sulfacetamide. Rats appear to be especially susceptible to the goitrogenic effects of sulfonamides, and long-term oral administration of sulfonamides has resulted in thyroid malignancies in these animals.

Pregnancy Animal reproduction studies have not been conducted with sulfonamide ophthalmic preparations. Kernicterus may occur in the newborn as a result of treatment of a pregnant woman at term with orally administered sulfonamides. There are no adequate and well-controlled studies of sulfonamide ophthalmic preparations in pregnant women, and it is not known whether topically applied sulfonamides can cause fetal harm when administered to a pregnant woman.

This product should be used in pregnancy only if the potential benefit justifies the potential risk to the fetus. Nursing Mothers Systemically administered sulfonamides are capable of producing kernicterus in infants of lactating women. Because of the potential for the development of kernicterus in neonates, a decision should be made whether to discontinue nursing or discontinue the drug taking into account the importance of the drug to the mother.

Pediatric Use Safety and effectiveness in infants below the age of two months have not been established.

🍼 Nursing Mothers 50 words ▾

Nursing Mothers Systemically administered sulfonamides are capable of producing kernicterus in infants of lactating women. Because of the potential for the development of kernicterus in neonates, a decision should be made whether to discontinue nursing or discontinue the drug taking into account the importance of the drug to the mother.

📄 Carcinogenesis, Mutagenesis, Impairment of Fertility 52 words ▾

Carcinogenesis, Mutagenesis, Impairment of Fertility No studies have been conducted in animals or in humans to evaluate the possibility of these effects with ocularly administered sulfacetamide. Rats appear to be especially susceptible to the goitrogenic effects of sulfonamides, and long-term oral administration of sulfonamides has resulted in thyroid malignancies in these animals.

📄 Package Label / Principal Display Panel 31 words ▾

PACKAGE/LABEL PRINCIPAL DISPLAY PANEL NDC 24208-670-04 Sulfacetamide Sodium Ophthalmic Solution, USP 10% (Sterile) FOR TOPICAL EYE USE ONLY Eye image symbol Rx only 15 mL BAUSCH + LOMB 9532102 AB0301 CARTON

Source: FDA Structured Product Labeling, mirrored from DailyMed / openFDA. Prefer the government’s original formatting? View this label on DailyMed ↗

Medicaid utilization & spend

📍 This exact package only: Medicaid data is reported per full 11-digit NDC — labeler, product and pack size — so every number here is for this package alone, not the drug overall. Other pack sizes report separately.
💊 Pharmacy benefit only: These are Medicaid outpatient pharmacy claims, billed by NDC. They exclude the medical benefit — clinic- or hospital-administered drugs billed under HCPCS J-codes — so drugs used mostly that way (e.g. Avastin, Lucentis, Keytruda) can look low or missing here. That’s expected, not an error.
📅 Q1 2025 – Q1 2026 · 5 quarters of data
ⓘ The newest quarter is usually incomplete when first published; states restate recent quarters in later CMS releases, so the latest figures typically revise upward. State coverage-policy changes can also shift quarter-to-quarter totals.
Prescriptions last 4 qtrs
10.4K
Units reimbursed last 4 qtrs
154.8K
Gross reimbursed last 4 qtrs
$388K
Avg / prescription
$37.27
Avg / unit
$2.5058
Latest quarter Q1 2026
2.2KRx
Medicaid pays / mL
$2.5058
gross reimbursed
vs
NADAC / mL
$1.9619
acquisition cost
=
Spread
+$0.5439
+28% vs cost
What Medicaid paid per mL (before rebates; includes the pharmacy’s dispensing fee) compared with NADAC — the average price pharmacies pay to buy the drug. A positive spread means Medicaid reimbursed more than the purchase price, before manufacturer rebates.
Fee-for-service vs managed care ⓘ
46% FFS 54% MCO
Fee-for-service · 4,743 Rx Managed care · 5,669 Rx
State Medicaid map
Alaska: no data reported AK Maine: no data reported ME Washington: 2,925 units · 37.4 per 100k residents WA Idaho: no data reported ID Montana: 228 units · 20.1 per 100k residents MT North Dakota: no data reported ND Minnesota: 1,576 units · 27.5 per 100k residents MN Wisconsin: 1,750 units · 29.6 per 100k residents WI Michigan: 8,850 units · 88.2 per 100k residents MI New York: 6,975 units · 35.6 per 100k residents NY Vermont: no data reported VT New Hampshire: 422 units · 30.1 per 100k residents NH Oregon: 2,835 units · 67.0 per 100k residents OR Nevada: 750 units · 23.5 per 100k residents NV Wyoming: no data reported WY South Dakota: no data reported SD Iowa: no data reported IA Illinois: 4,320 units · 34.4 per 100k residents IL Indiana: 8,152 units · 119 per 100k residents IN Ohio: 12,465 units · 106 per 100k residents OH Pennsylvania: 1,250 units · 9.6 per 100k residents PA New Jersey: 2,750 units · 29.6 per 100k residents NJ Massachusetts: 2,700 units · 38.6 per 100k residents MA California: 47,617 units · 122 per 100k residents CA Utah: no data reported UT Colorado: 1,815 units · 30.9 per 100k residents CO Nebraska: no data reported NE Missouri: 2,925 units · 47.2 per 100k residents MO Kentucky: 5,727 units · 127 per 100k residents KY West Virginia: no data reported WV Virginia: 1,680 units · 19.3 per 100k residents VA Maryland: 3,270 units · 52.9 per 100k residents MD Connecticut: 660 units · 18.2 per 100k residents CT Rhode Island: 345 units · 31.5 per 100k residents RI Arizona: 3,090 units · 41.6 per 100k residents AZ New Mexico: 2,070 units · 97.9 per 100k residents NM Kansas: 1,050 units · 35.7 per 100k residents KS Arkansas: no data reported AR Tennessee: 2,220 units · 31.2 per 100k residents TN North Carolina: 5,745 units · 53.0 per 100k residents NC South Carolina: 2,360 units · 43.9 per 100k residents SC Delaware: no data reported DE Oklahoma: 855 units · 21.1 per 100k residents OK Louisiana: 5,505 units · 120 per 100k residents LA Mississippi: no data reported MS Alabama: 3,250 units · 63.6 per 100k residents AL Georgia: 4,670 units · 42.3 per 100k residents GA D.C.: no data reported DC Hawaii: 690 units · 48.1 per 100k residents HI Texas: 1,350 units · 4.4 per 100k residents TX Florida: no data reported FL
Units reimbursed · per 100k residents
4.4127
gray = no data reported ⓘ
Colors are per 100,000 residents, so big states don’t automatically dominate. Tap or hover a state for its actual totals.
Tap or hover a state
…for its Medicaid breakdown
🏆 Top states by units · per 100k residents
1 Kentucky 127 /100k
2 California 122 /100k
3 Louisiana 120 /100k
4 Indiana 119 /100k
5 Ohio 106 /100k
6 New Mexico 97.9 /100k
7 Michigan 88.2 /100k
8 Oregon 67.0 /100k
National units — by quarter
💵 About the dollar figures: “reimbursed” is what Medicaid paid pharmacies before confidential manufacturer rebates, so the program’s real net cost is lower than these numbers. Fee-for-service and managed-care claims are combined unless split above. Source: CMS State Drug Utilization Data; per-100k rates use 2023 Census population estimates.

Medicare Part D spend CMS · PART D · 2026 (Q1)

Medicare Part D (outpatient prescription) spending for Sulfacetamide Sodium — the program that covers self-administered drugs. 3 manufacturers.
⚠️ Drug-level data: CMS publishes Part D spending by drug, not by NDC — these figures combine every manufacturer, strength and package size sold under the name Sulfacetamide Sodium. That’s a different level of aggregation than the Medicaid card above, which is specific to this exact 11-digit NDC (pack size included), so the two aren’t directly comparable.
Period
Total Part D spend
$399.5K
Claims incl. refills
6.9K
Beneficiaries
6.1K
Spend / beneficiary
$65.03
Spend / claim
$57.85
Trend by period
💵 About the dollar figures: spending is what Part D plans paid before confidential manufacturer rebates, so the program’s real net cost is lower. A blank patient count means fewer than 11 people — CMS hides counts that small to protect privacy. Source: CMS Medicare Quarterly Part D Spending by Drug (data.cms.gov), updated quarterly.

Reported adverse events (FAERS)

Read carefully: FAERS reports are voluntary and unverified. Counts are not incidence, do not establish causation, are subject to reporting bias, and cannot be used to compare one drug to another. Shown for signal context only. Reports for SULFACETAMIDE SODIUM — the ingredient across all brands.

Top reported reactions

Drug Hypersensitivity64
Nausea35
Dyspnoea32
Headache32
Rash29
Pain27
Weight Decreased24

Age at onset

Neonate1
Adolescent4
Adult52
Elderly24

Reporter sex

601 reports
Male · 31%
Female · 69%
Unknown · 0%

Serious outcomes

Hospitalization103
Death14
Disabling12
Life-threatening8
Reports over time (by year) — tap or hover for the count & year
2019 2021 2023 2026 54 25
Most recent year is provisional (FAERS lags ~3 months).
Where does this data come from?
Adverse-event reports from the FDA Adverse Event Reporting System (FAERS) via openFDA. FAERS reports are voluntary and unverified — counts are not incidence and don’t establish causation.
← 24208-0635-62 · Bausch 24208-0715-10 · Bausch →
For educational and professional reference only — not medical advice. Pricing reflects published NADAC and CMS ASP (free public data) and may differ from your acquisition cost; always verify before billing or dispensing.